Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The process generally involves an initial physician review, followed by the prescription of GLP-1 medications if deemed appropriate
Prior authorizations, insurance rejections, and coverage clarifications are more frequent for obesity indications
Your prescriber may adjust timing based on how you tolerate each dose
Designed to preserve stability until first use
Missing are direct head-to-head studies comparing the two drugs
DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 USD 170.75 BN MARKET SIZE, 2033 OVERVIEW Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period
US$ 24.87
US$ 20.77
US$ 24.80
US$ 21.22
US$ 26.96
US$ 27.28
US$ 28.31
US$ 24.82
US$ 22.59
US$ 25.61
